Kura Oncology和Kyowa Kirin宣布Komzifti™(Ziftomenib)获得FDA的批准,成为首个也是唯一每日一次的针对成人复发或难治性Npm1突变急性髓性白血病的靶向治疗。
Kura Oncology和Kyowa Kirin宣布Komzifti™(Ziftomenib)获得FDA的批准,成为首个也是唯一每日一次的针对成人复发或难治性Npm1突变急性髓性白血病的靶向治疗。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.